How to Effectively Manage a Product Recall - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

How to Effectively Manage a Product Recall
The authors group key actions to consider when conducting a product recall and discuss how to execute them carefully and thoroughly.


Pharmaceutical Technology
Volume 35, Issue 1

When is the product recall officially ended?

Recall communications have gone out, consignees have responded, product has been returned, status reports have been submitted, effectiveness checks have been completed. One might think the recall is now over, however, that is not something a company can decide. The official recall termination notice must come from FDA. A company can request that the recall be terminated by submitting a recall summary report stating that all efforts have been exhausted for the product retrieval and justifying that the recall strategy has been successfully and completely implemented. If FDA agrees, the recall termination letter will be sent by FDA to the recalling company.

Product recalls are very time consuming, requiring cooperation, organization, and levelheadedness for a company to survive relatively unscathed. Resources are often stretched to accommodate the increased requirements and the company usually becomes under increased scrutiny by FDA from a compliance perspective.

No company wants to be involved in a product recall. However, if the situation is unavoidable, proper training, planning, and execution of the recall can result in only minor operational and financial disruption.

Nancy Cafmeyer is a project manager, and Jonathan M. Lewis is a principal, both at Advanced Biomedical Consulting (ABC), St. Petersburg, FL, tel. 888.671.4292, fax 888.316.7537,
http://www.abcforfda.com/.

References

1. Code of Federal Regulations, Title 21, Food and Drugs, Chapter 1 – Subchapter A – General (Government Printing Office, Washington, DC), Part 7

2. FDA, Guidance for Industry: Product Recalls, Including Removals and Corrections, (Rockville, MD, Nov. 3, 2003).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
20%
To all process for new products only
13%
To select process for new products only
24%
To select processes for both new and legacy products
20%
Do not use QbD
22%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Inadequate Access to Medicines Puts EU at Risk
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here